Cara Therapeutics Announces Participation in 2018 Spring Clinical Meetings of the National Kidney Foundation
April 10 2018 - 07:00AM
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company
focused on developing and commercializing new chemical entities
designed to alleviate pruritus and pain by selectively targeting
peripheral kappa opioid receptors, today announced presentations at
the 2018 Spring Clinical Meetings of the National Kidney
Foundation, to be held April 10-14, 2018 in Austin.
The presentations will include data from the
Company’s clinical trials of KORSUVA™ (CR845/difelikefalin)
injection in hemodialysis patients with moderate-to-severe chronic
kidney disease-associated pruritus. KORSUVA is Cara's
first-in-class kappa opioid receptor agonist that targets the
body’s peripheral nervous system, as well as certain immune
cells.
Details for the presentations are as
follows:
Poster Presentation:
Title:
"Clinically Meaningful Itch Reduction By CR845: An
8-Week Randomized, Placebo-Controlled Study in Hemodialysis
Patients”Date / Time:
Wednesday, April 11, 2018; 6-7:30 p.m. CDT
Presenter:
Catherine Munera,
Head of Biometrics, Cara Therapeutics
Exhibitor Showcase:
Title:
"CKD-Associated Pruritus is Underrecognized and
Undertreated: An Itch Your Patients Can’t Ignore”Date /
Time:
Thursday, April 12, 2018; 1:15-1:50 p.m. CDT
Presenters:
Joseph Stauffer, DO,
MBA, Chief Medical Officer, Cara
Therapeutics
Geoffrey A. Block,
MD, Director of Clinical Research, Denver Nephrology
Research Division, Associate Professor, Department of Medicine,
University of Colorado Health Sciences Center
For information about the 2018 Spring Clinical
Meetings of the National Kidney Foundation, visit
https://www.kidney.org/spring-clinical.
About Cara
Therapeutics
Cara Therapeutics is a clinical-stage
biopharmaceutical company focused on developing and commercializing
new chemical entities designed to alleviate pruritus and pain by
selectively targeting peripheral kappa opioid receptors (KORs).
Cara is developing a novel and proprietary class of product
candidates, led by KORSUVA™ (CR845/difelikefalin), a
first-in-class KOR agonist that targets the body's peripheral
nervous system, as well as certain immune cells. In Phase 2 trials,
KORSUVA injection has demonstrated statistically significant
reductions in itch intensity and concomitant improvement in quality
of life measures in hemodialysis patients with moderate-to-severe
chronic kidney disease-associated pruritus (CKD-aP) and is
currently being investigated in Phase 3 trials in hemodialysis
patients with CKD-aP. Additionally, CR845/difelikefalin has
demonstrated initial signs of efficacy in patients with
moderate-to-severe pain, without inducing many of the undesirable
side effects typically associated with currently available opioid
pain therapeutics.
The FDA has conditionally accepted
KORSUVA™ as the trade name for difelikefalin injection.
CR845/difelikefalin is an investigational drug product, and its
safety and efficacy have not been fully evaluated by any regulatory
authority.
INVESTOR CONTACT:Michael SchaffzinStern
Investor Relations212-362-1200michael@sternir.com
MEDIA CONTACT:Annie Starr6 Degrees973-415-8838
astarr@6degreespr.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Mar 2023 to Mar 2024